PMID- 10960673
OWN - NLM
STAT- MEDLINE
DCOM- 20001113
LR  - 20190921
IS  - 0162-3109 (Print)
IS  - 0162-3109 (Linking)
VI  - 48
IP  - 3
DP  - 2000 Jul 25
TI  - Immunotherapy approach to allergic disease.
PG  - 307-10
AB  - The causal role of immunoglobulin E (IgE) in triggering the cascade of 
      biochemical events leading to allergic disease is well established. Treatments 
      that selectively inhibit IgE activity are a logical approach in managing the 
      allergic response. One such strategy utilizes rhuMAb-E25, a recombinant humanized 
      IgG(1) monoclonal anti-IgE antibody, which binds to IgE. This anti-IgE antibody 
      binds at the same epitope site of IgE that binds to FcvarepsilonRI and is thus 
      non-anaphylactogenic. By binding to IgE and removing it via immune complex 
      formation, the pool of IgE available to interact with mast cells and basophils is 
      thereby reduced and the allergic response is attenuated. The clinical safety and 
      efficacy of rhuMAb-E25 demonstrated in phase II studies of allergic asthma will 
      be outlined.
FAU - Fick, R B Jr
AU  - Fick RB Jr
AD  - Genentech Inc., 1 DNA Way, South San Francisco CA 94080-4990, USA.
FAU - Fox, J A
AU  - Fox JA
FAU - Jardieu, P M
AU  - Jardieu PM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Immunopharmacology
JT  - Immunopharmacology
JID - 7902474
RN  - 0 (Allergens)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (rhuMAb-E25)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Allergens/pharmacology/*therapeutic use
MH  - Animals
MH  - Antibodies, Monoclonal/pharmacology/*therapeutic use
MH  - Humans
MH  - Hypersensitivity/*drug therapy
MH  - Immunoglobulin E/*blood/drug effects
MH  - Immunotherapy/*methods
RF  - 7
EDAT- 2000/08/29 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/08/29 11:00
PHST- 2000/08/29 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/08/29 11:00 [entrez]
AID - S0162310900002290 [pii]
AID - 10.1016/s0162-3109(00)00229-0 [doi]
PST - ppublish
SO  - Immunopharmacology. 2000 Jul 25;48(3):307-10. doi: 10.1016/s0162-3109(00)00229-0.